- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05709756
Prevalence and Predictors of Esophageal Thermal Lesions in High-power-Short-duration Ablation of Atrial Fibrillation (VISUAL-AF)
Prevalence and Predictors of Esophageal Thermal Lesions in High-Power-Short-Duration Ablation of Atrial Fibrillation
Patients with documented atrial fibrillation who were referred to our clinic for catheter ablation will undergo standard HPSD ablation and subsequent esophagoscopy.
After esophagoscopy patients will be followed up for one month in the form of a telephone follow-up.
The primary endpoint of the study assessed by esophagoscopy performed on the day after the index catheter ablaton is the incidence of esophageal thermal lesions.
Secondary endpoints include:
- The size of the esophageal thermal lesions.
- The severity of esophageal thermal lesions.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Arash Arya, MD
- Phone Number: +49341865252009
- Email: arash.arya@helios-gesundheit.de
Study Locations
-
-
Saxony
-
Leipzig, Saxony, Germany, 04289
- Arash Arya
-
Leipzig, Saxony, Germany, 04289
- Department of Electrophysiology, Leipzig Heart Center at University of Leipzig
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Atrial fibrillation documented in the 12-lead ECG
- Indication for catheter ablation in accordance with currentn ESC guidelines
Exclusion Criteria:
- Pregnancy
- Women of childbearing potential without a negative pregnancy test within 48 hours prior to ablation procedure
- Known intracardiac or other thrombi
- Contraindication to anticoagulation
- Contraindication to esophagoscopy: diseases and deformities of the cervical spine, esophageal varices
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence of ablation-related esophageal thermal lesions
Time Frame: One day after Catheter ablation
|
It will be assessed by means of Esophagoscopy
|
One day after Catheter ablation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Size of ablation-related esophageal thermal lesions
Time Frame: One day after Catheter ablation
|
It will be assessed by means of Esophagoscopy
|
One day after Catheter ablation
|
Severity of ablation-related esophageal thermal lesions
Time Frame: One day after Catheter ablation
|
It will be assessed by means of Esophagoscopy
|
One day after Catheter ablation
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Gerhard Hindricks, MD, Leipzig Heart Center at University of Leipzig
- Study Director: Arash Arya, MD, Leipzig Heart Center at University of Leipzig
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 549/20-ek
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
St. George's Hospital, LondonRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited Kingdom
-
R-PharmFSBI "National Medical Research Center of Cardiology named after academician...CompletedAtrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationRussian Federation